Validation and Application of a Module of the M. D. Anderson Symptom Inventory for Measuring Multiple Symptoms in Patients With Gastrointestinal Cancer (the MDASI-GI)

被引:99
作者
Wang, Xin Shelley [1 ]
Williams, Loretta A. [1 ]
Eng, Cathy [2 ]
Mendoza, Tito R. [1 ]
Shah, Nyma A. [1 ]
Kirkendoll, Karyn J. [1 ]
Shah, Pankil K. [1 ]
Trask, Peter C. [3 ]
Palos, Guadalupe R. [1 ]
Cleeland, Charles S. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA
[3] Pfizer Inc, Global Outcomes Res, New London, CT USA
关键词
cancer; symptoms; assessment; validation; gastrointestinal; M. D. Anderson Symptom Inventory; REPORTED OUTCOMES; INSTRUMENT; DISTRESS; PREVALENCE; BURDEN;
D O I
10.1002/cncr.24920
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The M. D. Anderson Symptom Inventory (MDASI) was developed as a brief yet comprehensive tool to assess patient-reported symptom severity and interference in patients with cancer. The authors report the development of an MDASI module for use in patients with gastrointestinal (GI) cancer (the MDASI-GI). METHODS: Patients with GI cancer (N = 184) participated in module development and validation. The process included: 1) generating GI-specific candidate items with input from GI oncologists and from qualitative interviews with patients and adding those items to the core MDASI for testing; 2) dropping candidate GI items that lacked sensitivity; 3) validating the psychometric properties (validity, reliability, sensitivity) of the resulting MDASI-GI; and 4) conducting cognitive debriefing interviews with patients to confirm the questionnaire's ease of comprehension, relevance, and acceptability. RESULTS: Five GI-specific symptom items (constipation, diarrhea, difficulty swallowing, change in taste, and feeling bloated) were added to the original 19 MDASI symptom and interference items to form the MDASI-GI. Sixty-one percent of the sample had 1 or more moderate-to-severe symptom(s) (>= 5 on a severity scale from 0 to 10). Cronbach a values were .80 and .87 for symptom severity items and interference items, respectively. Known-group validity (sensitivity) was supported by the ability of the MDASI-GI to detect significant differences in symptom and interference levels according to performance status (P < .001). Cognitive debriefing demonstrated that for patients, the MDASI-GI was an easy-to-use and understandable tool. CONCLUSIONS: The current results indicated that the MDASI-GI is a valid, reliable, and concise tool for measuring symptom severity and interference with function in patients with GI cancer. Cancer 2010;116:2053-63. (c) 2010 American Cancer Society.
引用
收藏
页码:2053 / 2063
页数:11
相关论文
共 35 条
  • [1] [Anonymous], J CANC INTEGR MED
  • [2] Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT)
    Armstrong, T. S.
    Mendoza, T.
    Gring, I.
    Coco, C.
    Cohen, M. Z.
    Eriksen, L.
    Hsu, Ming-Ann
    Gilbert, M. R.
    Cleeland, C.
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2006, 80 (01) : 27 - +
  • [3] Symptom cluster research: Conceptual, design, measurement, and analysis issues
    Barsevick, AM
    Whitmer, K
    Nail, LM
    Beck, SL
    Dudley, WN
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2006, 31 (01) : 85 - 95
  • [4] Borden EC, 1998, SEMIN ONCOL, V25, P3
  • [5] Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129
  • [6] Cleeland Charles S, 2007, J Natl Cancer Inst Monogr, P16
  • [7] Cancer-related symptoms
    Cleeland, CS
    [J]. SEMINARS IN RADIATION ONCOLOGY, 2000, 10 (03) : 175 - 190
  • [8] Cleeland CS, 2000, CANCER-AM CANCER SOC, V89, P1634, DOI 10.1002/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO
  • [9] 2-V
  • [10] MEASURING PSYCHOLOGICAL AND PHYSICAL DISTRESS IN CANCER-PATIENTS - STRUCTURE AND APPLICATION OF THE ROTTERDAM-SYMPTOM-CHECKLIST
    DEHAES, JCJM
    VANKNIPPENBERG, FCE
    NEIJT, JP
    [J]. BRITISH JOURNAL OF CANCER, 1990, 62 (06) : 1034 - 1038